Subglottic cysts can cause stridor and respiratory distress in the infant. The diagnosis of subglottic cysts is often confi rmed during direct laryngoscopy and bronchoscopy. We describe the case ofa 6-month-old boy with bilateral subglottic cysts that were preoperatively diagnosed by magnetic resonance imaging (MR/). We also review the current literature on the diagnosis and treatment ofsubglottic cysts. Up until now, 63 cases ofsubglottic cysts were reported in the literature since 1966, and most were diagnosed by direct endoscopy. In this article, we describe a new case and we provide thefirst publish ed report of the novel use of MRI in diagnosing this lesion.
enhanced magnetic resonance imaging (MRI) in the preoperative diagnos is of subglottic cysts. Our use of MRI allowed for more effective preoperative cou nseling of the parents and enhanced our ability to choo se an appropriate surgical procedure. We also review the relevant literature relating to subglottic cysts and their radio logic diagno sis.
Case report
A white boy born at 37 weeks ' gestation had been intubated for 2 days during the neonat al period. When he was 2 months of age, he was taken to a pediatric pulmonologist for evaluation of stridor. He was treated with a course of steroids, and he showed improvement. When he reached 6 months of age, his symptoms slowly returned and he was again taken for medical care. Flexib le bronchoscopy revea led the prese nce of bilateral subglottic masses in the posterolateral aspect of the subglottis. The family was resistant to any operative interve ntion, includin g tracheostomy to stabilize the child's airway before further manageme nt could be undertaken.
Reluctant to proceed with any surgery, the family soug ht consultation for less invasive management at the pediatric otolary ngology service of our institution. After examining the child, we obtained an MRI with gadolinium contrast to further evaluate the substance of the subglottic space and to assist in further coun seling of the family regarding surgical management. MR I revealed the presence of two subglottic masses whose radiologic appear ance was cons istent with that of a cyst (figure 1).
The family was then coun seled that tracheostomy would be performed only if rigid broncho scopy revealed that a more conservative treatment would endanger the child . Direct laryngoscopy and bronchoscopy confirmed the presence of bilateral subglottic cysts (figure 2).
The cysts were successfully marsupialized with a pediatric Healy subglottiscope and a CO 2 laser (figure 3). Repeat bronchoscopy 2 months later showed that the airway was norma l in caliber and appearance. The child In clinical trials , using the recommended dose , the overall incidence of adverse events was comparable to vehicle placebo. The most commonly reported adverse events , not necessarily drug related , were, for NASONEX' and vehicle placebo , respectively: headache (17 -26% vs 18722%), viral infection (8-14% vs 9-11%), pharyngitis (10-12% vs 10%), epistaxis/blood-tinged mucus (8-11% vs 6-9%), and coughing (7-13% vs 6-15%). Wal lnfeetion  14  11  8  9  Pharyngitis  12  10  10  10  Epistax isIBloo<I·  nngedMucus  11  6  8  9  Coughing  7  6  13  15  UpperRespiratory  TractInf eelion  6  2  5  4  Dysmenorrhea  5  3  1  0  Musculoskelelal  Pain  5  3  1  1  Sinusitis  5  3  4  4  Vomiting  1  1  5  4 Other adverse eventswhich occurred inless than 5% but greater than or equal to 2" /. of mometasone luroate adull an d ad ol escenl patienls (ages 12yearsandol der) treated ,nth 2OQ-mcg doses(regardless 01 relati onshipto Ireatment ),andmore trequentlythan inthe p~cebo group inc luded:arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, dyspepsia, earache, flu· likesymptoms, myalgia, nausea, andrhinitis.
Other adverse events which occurredinless than5% but greater than or equalto2%of mometasone furoatepediatric pal ienlsages 3to11years treat· ed ,nih lOO·mcg doses vsplacebo (regardless of relationship totreatment) and more lrequently thaninthe p~cebo group included: diarrhea, nasal irrita · lion,otitis medi a, and wheezing.
Rarecases ofnasal ulcers andnasal and oral candidiasiswere al so report · ed inpatientstreated"nthNASONEX NasalSpray,50meg,primanlyinpatien lS treatedforlongerthan 4\'leeks.
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Review of published cases
We conducted a Medline search to identify all case reports and other relevant articles on subglottic cysts in infants that have been published since 1966 . Including ours, 64 cases were available for review (table) . Whenever the information was noted in the original article, we recorded the number of days of intubation, the number of months postintubation until the patient was subsequently evaluated for cysts, the type of treatment, and the number of recurrences.
The number of days of intubation ranged from I to 90 (mean: . 26 .2) . The number of months to postintubation cyst evaluation ranged from 1.5 to 25 (mean : 8). The vast majority of patients were diagnosed by direct laryngoscopy without the use of adjuvant imaging. Two reports mentioned the use of soft-tissue lateral neck x-rays to assist in the work-up.l-' ?No article reported the use of computed tomography (CT) or MRI to assist in the diagnosis .
Most subglottic cysts were managed endoscopically by direct rupture, laser excision, marsupialization, or removal with cupped forceps. Six of these patients (9.4%) underwent staged endoscopic procedures. v? Thirteen patients (20 .3%) required tracheostomy. v -'<"-" three patients (4.7 %) underwent an anterior cricoid split," and three others were treated with laryngotracheal reconstruction; " Six patients (9.4 %) died; in three of them, the subglottic cysts were discovered for the first time at autopsy .I.2.7.8.1O There were 11 reported recurrences (17.2%). 4.7.8.1 \,l3
Discussion
The incidence of subglottic cysts appears to be increasing. Our review of the English-language literature published from 1966 through 1989 found only 23 reported cases. Since 1990, the number of reported cases, including ours, is 41 . Thi s increase in the number of patients diagnosed with subglottic cysts is thought to be related to improvements in survival of very premature infants. Although the pathogenesis of subglottic cysts is not completely und erstood, it appears to be strongly associated with early intubation.
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Intubation can lead to damage of the laryngeal, subglottic , and tracheal mucosa within only a few days. In a study of postmortem infants, Hawkins found that after as few as 6 days of intubation, 93 % of examined airways showed signs of subglottic ulceration, squamous metaplasia, and resultant subepithelial fibrosis." It is believed that this mucosal damage leads to scarring and eventual occlusion of the ducts of the submucosal glands. The occluded glands continue to produce mucus, which leads to the formation of retention cysts. Eve n only I or 2 days of intubation can be sufficient to lead to the development of subglottic cysts . Smith et aI,I I To riumi et aI,7 and Tierney et al" reported that subglottic cysts had deve loped in children who had been intubated for only 1, 2, and 3 days, respectively. Moreover, in their report of 11 patients with subglottic cys ts, Smith et al found no relationship betwee n the duration of intubation and the severi ty of the cysts."
As is the case in most infants with airway distress, an acc urate diagnosis is draw n from the history, physica l examination, and an appropriate level of suspicion. A diagnosis of subglo ttic cys ts should be cons idered in all patients who have a history of intubation, regardless of its duration. The defin itive diagnosis is made during direct laryngoscopy and bronchoscopy. Children with suspecte d pathology below the level of the true voca l fol ds should undergo endoscopy because it is considered to be part of the complete physical exa mination of the airway.
Our review of the literature provided little information abo ut the role that imagi ng might play in the preo perative assessment of these patients. Reed and Myer published one of the few articles that discussed the use of radiography to assist in the diagnosis of subglottic cysts prior to endoscopy.FT hey discussed plain soft-tissue radiographs of the neck, but made no comme nt on the role of CT or MRI.
On MRI, subglottic cysts have distinct characteristics that help differentiate them fro m other subg lottic pathol- ogy. MRI appears to be superior to CT in the evaluation of cystic and soft-tissue pathology of the larynx because of its ' multiplanar capability, contrast resolution, and ability to demonstrate the full extent of the mass and its relationship to vascular and soft-tissue structures in all compartments of the neck. On T2-weighted images, the signal intensity is high ( figure I, A) . On Tl-weighted images, the fluid content of the subglottic cysts has a low signal intensity , similar to that of water. Following the administration of gadolinium to our patient, there was no enhancement of the cysts ( figure I, B ). The characteristic appearance and location of subglottic cysts on MRI helps to distinguish them from thyroglossal duct cysts, branchial cleft cysts, cystic hygromas, dermoid cysts, and other neck pathologies. Hemangiomas can mimic subglottic cysts, but on MRI they appear as soft-tissue masses and are characterized by intermediate signal intensity (related to muscle) on T l-weighted imaging and by high signal intensity on T2-weighted imaging. Also, MRI can demonstrate multiple areas of signal void in the hemangiomas, which represent vessels. After the administration of gadolinium contrast, these masses enhance homogenously. Soft-tissue stenosis of the subglottic region appears as areas of narrowing, without associated mass effect or abnormal enhancement.
The importance of radiologic preoperative assessment cannot be overstated. Most subglottic cysts can be treated endoscopically without the need for open tracheal reconstruction or tracheostomy. Two of the three patients in our review who underwent laryngotracheal reconstruction had been diagnosed with soft-tissue subglottic stenosis ." In both cases, the cysts were discovered during the reconstruction. The authors made no mention of the role that imaging might have played in helping differentiate subglottic stenoses from subglottic cysts. Unlike subglottic cysts, soft-tissue stenoses more often require temporary tracheostomy and subsequent tracheal reconstruction. The distinct imaging characteristics of soft-tissue stenoses and subglottic cysts on MRI aid in their differentiation. Again, the use of MRI can help determine which type of procedure should be performed and whether a tracheostomy will be necessary.
The character of subglottic cysts can usually be appreciated on direct endoscopy. These cysts can appear singly or multiply in a variety of locations in the subglottis. Nevertheless, it is important to remember that subglottic cysts are not always obvious during endoscopy, and those that occur deeper in the submucosal tissues can be missed. To date, four cases of subglottic cysts that were not initially recognized on initial endoscopy have been reported .P-" Each of these patients underwent tracheostomy for what was believed to be a soft-tissue subglottic stenosis . The cysts were later recognized during laryngotracheal reconstruction (2 patients laryngobronchoscopy (l patient), and at autopsy (l patient). The realization that subglottic cysts can be missed during endoscopy adds support to the use of MRI in selected case s as an adjunct to preoperative evaluation. With regard to the treatment options at the time of endoscopy-direct rupture , laser ablation, marsupialization, removal by cupped forceps, and occasionally tracheostomy-our review did not find that one was superior to any other, nor did we find an association between the particular type of surgical procedure and the incidence of recurrence. Likew ise, the use of staged endoscopic procedures also had no affect on the recurrence rate. We advocate that follow-up endoscopy be performed to rule out recurrence and to evaluate the patency of the patient's airway .
In conclusion, our inve stigation should not be interpreted as an endorsement for replacing pediatric broncho scopy with MRI. However, our work does indicate that the use ofMRI in selected patients can confirm the diagnosis of subglottic cysts preoperatively and help differentiate them from other subglottic patholog y. This should allow for a more informed parental counseling and a more directed formulation of a surgic al plan. The clinician is encouraged to consider MRI whenever there is a reluctance to proceed to the operating room or whenever the etiology of subglottic pathology is not certain. Otovent can prevent or treat Otiti s m edia and can be a n alt ernative to surg ery.
Proven su cce ss in clini cal study. 
